Regarding the treatment of smoking‐induced cancers, selective nAChR antagonists may hold potential by precisely targeting overexpressed nAChR subunits in cancer cells and minimizing adverse effects on healthy tissues, with α7‐nAChR antagonists having been shown to inhibit lung cancer [5]. This evidence concerns the gene CHRNA7 and lung cancer.